Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evotec AG

www.evotec.com

Latest From Evotec AG

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter. 

Deals Financing

Galapagos Targets Liver Fibrosis With Evotec Deal

Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.

 

Clinical Trials Deals

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.

Business Strategies Commercial

Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform

Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.

Financing StartUps and SMEs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register